Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farzam Kamgar

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Medical Economics|February 22, 2024
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placeboSiguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, et al.
Journal of Medical Economics|March 12, 2024
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspectiveThor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2024
IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's DiseaseRon Handels, William L Herring, Farzam Kamgar, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Medical Economics|February 22, 2024
Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placeboSiguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, et al.
Journal of Medical Economics|March 12, 2024
Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspectiveThor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 9, 2024
IPECAD Modeling Workshop 2023 Cross-Comparison Challenge on Cost-Effectiveness Models in Alzheimer's DiseaseRon Handels, William L Herring, Farzam Kamgar, et al.
Pageof 1